Table 1.
Study population’s characteristics.
| Overall (n=102) | SOT Type | P value | |||||
|---|---|---|---|---|---|---|---|
| Kidney (n=52) | Liver (n=50) | ||||||
| Age at time of the first dose (yrs) | 102 | 60.7 ± 9.9 | 52 | 57.5 ± 10.8 | 50 | 64.0 ± 7.7 | 0.001 |
| Gender (% M) | 71 (69.6%) | 34 (65.4%) | 37 (74.0%) | 0.393 | |||
| Previous COVID-19 | 2 (2.0%) | 2 (3.8%) | 0 | 0.495 | |||
| Months elapsed since transplantation | 102 | 125.6 ± 154.1 | 52 | 110.5 ± 79.0 | 50 | 141.4 ± 204.9 | 0.959 |
| BMI (Kg/m2) | 77 | 25.2 ± 4.6 | 52 | 24.6 ± 4.1 | 25 | 26.3 ± 5.4 | 0.140 |
| Donor type (% Living) | 9 (8.8%) | 9 (17.3%) | 0 | 0.003 | |||
| Induction therapy | |||||||
| No Induction | 39 (38.2%) | 9 (17.3%) | 30 (60.0%) | <0.001 | |||
| ATG | 30 (29.4%) | 30 (57.7%) | 0 | ||||
| Basiliximab | 33 (32.4%) | 13 (25.0%) | 20 (40.0%) | ||||
| Tacrolimus | 84 (82.4%) | 46 (88.5%) | 38 (76.0%) | 0.123 | |||
| Cyclosporine | 13 (12.7%) | 6 (11.5%) | 7 (14.0%) | 0.773 | |||
| mTOR-inhibitors | 24 (23.5%) | 9 (17.3%) | 15 (30.0%) | 0.164 | |||
| MMF | 57 (55.9%) | 41 (78.8%) | 16 (32.0%) | <0.001 | |||
| Steroids | 43 (42.2%) | 40 (76.9%) | 3 (6.0%) | <0.001 | |||
| Tacrolimus trough levels (ng/mL) | 84 | 5.2 ± 2.0 | 46 | 6.2 ± 1.4 | 38 | 3.9 ± 1.8 | <0.001 |
| Cyclosporine trough levels (ng/mL) | 14 | 111.1 ± 116.9 | 6 | 80.0 ± 9.7 | 8 | 134.4 ± 154.4 | 1.000 |
| mTOR-inhibitors trough levels (ng/mL) | 9 | 4.1 ± 1.2 | 7 | 3.7 ± 0.9 | 2 | 5.6 ± 0.6 | 0.111 |
| MMF dosage (mg/day) | 58 | 834.3 ± 556.4 | 42 | 741.2 ± 298.1 | 16 | 1078.8 ± 919.5 | 0.349 |
| History of treatment for rejection | 5 (4.9%) | 0 | 5 (10.0%) | 0.025 | |||
| Cause of ESKD | |||||||
| Glomerular disease | 9 (17.3%) | 9 (17.3%) | 0 | ||||
| ADPKD | 15 (28.8%) | 15 (28.8%) | 0 | ||||
| Other Congenital/Pyelonephritis/Interstitial nephritis | 6 (11.5%) | 6 (11.5%) | 0 | ||||
| Nephroangiosclerosis | 4 (7.7%) | 4 (7.7%) | 0 | ||||
| Systemic vasculitis | 1 (1.9%) | 1 (1.9%) | 0 | ||||
| Other | 17 (32.7%) | 17 (32.7%) | 0 | ||||
| Cause of liver failure | |||||||
| Alcoholic cirrhosis | 11 (22.0%) | 0 | 11 (22.0%) | ||||
| HBV +/- HDV cirrhosis | 12 (24.0%) | 0 | 12 (24.0%) | ||||
| HCV cirrhosis | 14 (28.0%) | 0 | 14 (28.0%) | ||||
| HBV + HCV cirrhosis | 2 (4.0%) | 0 | 2 (4.0%) | ||||
| Alcoholic + HCV and/or HBV +/- HDV | 3 (6.0%) | 0 | 3 (6.0%) | ||||
| PBC or PSC | 5 (10.0%) | 0 | 5 (10.0%) | ||||
| Cryptogenic or dysmetabolic cirrhosis | 3 (6.0%) | 0 | 3 (6.0%) | ||||
| Previous cancer | 37 (36.3%) | 18 (34.6%) | 19 (38.0%) | 0.837 | |||
| Autoimmune disease | 1 (1.0%) | 0 | 1 (2.0%) | 0.490 | |||
Continuous data are reported as number of nonmissing variables, mean ± SD; categorical data are reported as number of nonmissing variables and percentages. SOT, solid organ transplant; ATG, anti-thymocyte globulin; MMF, mycophenolate mofetil; ESKD, end stage kidney disease; ADPKD, autosomal dominant polycystic kidney disease; HBV, hepatitis B virus; HDV, hepatitis D virus; HCV, hepatitis C virus; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis.